Obexelimab治疗系统性红斑狼疮及基于基因通路共表达模式探索应答:一项双盲、随机、安慰剂对照2期试验
本2期试验将104例活动性、非器官威胁性SLE患者随机分配至obexelimab 5 mg/kg静脉注射或安慰剂组,每2周一次至第32周或丧失改善。主要终点(第32周未丧失改善比例)未达统计学显著:obexelimab组42.0% vs 安慰剂组28.6%(P=0.183)。次要分析显示obexelimab组至丧失改善时间显著延长(HR 0.53,P=0.025),且基线基因表达高B细胞通路模块患者应答更佳。
要点
- 主要终点第32周未丧失改善比例组间无显著差异:obexelimab组42.0% vs 安慰剂组28.6%(P=0.183)。
- 至丧失改善时间在obexelimab组显著延长(HR 0.53,P=0.025)。
- obexelimab治疗使B细胞减少约50%,输注反应较常见但总体安全可耐受。
核心结论
- 主要终点未达到,但次要分析显示obexelimab组至丧失改善时间显著延长,基线基因表达模式分析提示存在应答亚群。
研究设计与样本
- 双盲、随机、安慰剂对照2期试验,104例活动性、非器官威胁性SLE患者按1:1随机接受obexelimab 5 mg/kg静脉注射或安慰剂,每2周一次至第32周或丧失改善。
主要发现
- 主要终点第32周未丧失改善比例:obexelimab组21/50(42.0%)vs 安慰剂组12/42(28.6%),P=0.183,未达统计学显著。
- 至丧失改善时间:疗效可评估人群中obexelimab组较安慰剂组延长(HR 0.53,P=0.025);意向治疗人群中HR 0.59,P=0.062。
- obexelimab治疗患者B细胞减少约50%,谷浓度及基线基因表达聚类中高B细胞通路模块与至丧失改善时间延长相关。
- obexelimab与输注反应相关,但总体安全且耐受良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Obexelimab is an investigational, bifunctional, noncytolytic monoclonal antibody that binds CD19 and FcyRIIb to inhibit B cells, plasmablasts, and plasma cells. This trial evaluated the efficacy and safety of obexelimab in the treatment of patients with systemic lupus erythematosus (SLE). METHODS: During screening, patients with active, non-organ-threatening SLE received corticosteroid injections to ameliorate symptoms while immunosuppressants were withdrawn (≤10 mg/day prednisone equivalent and ≤400 mg/day hydroxychloroquine allowed). Patients with improved disease activity were randomized 1:1 to obexelimab 5 mg/kg intravenously or placebo once every 2 weeks until week 32 or loss of improvement (LOI). RESULTS: In this study, 104 patients were randomized. Analysis of the primary endpoint, proportion of patients reaching week 32 without LOI, used an efficacy-evaluable (EE) population defined as patients who completed the study or withdrew for flare or treatment-related toxicity. This endpoint did not reach statistical significance: 21 of 50 obexelimab-treated patients (42.0%) versus 12 of 42 patients (28.6%) treated with a placebo (P = 0.183). Time to LOI was increased in obexelimab-treated patients versus patients treated with a placebo in the EE (hazard ratio [HR] 0.53, P = 0.025) and intention-to-treat (HR 0.59, P = 0.062) populations. In obexelimab-treated patients, B cells decreased approximately 50%, and trough concentration and inclusion in baseline gene expression clusters with high B cell pathway modules were associated with increased time to LOI. Obexelimab was associated with infusion reactions but was generally safe and well-tolerated. CONCLUSION: Although the primary endpoint was not reached, secondary analysis showed time to LOI was significantly increased in obexelimab-treated patients, and analysis of patient subsets defined by gene expression patterns at baseline suggests a responding subpopulation.
引用
- Merrill JT, Guthridge J, Smith M, et al. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Arthritis Rheumatol. 2023. PMID: 37459248. doi:10.1002/art.42652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。